secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001140361-25-041807
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics reports Q2 loss of $0.9M; FDA accepts NDA for GTx-104 with PDUFA April 23, 2026
--------------------------------------------------------------------------------

- Net loss $0.9M ($0.06 loss per share) vs $3.4M ($0.30 loss) in Q2 last year.
- FDA accepted NDA for GTx-104 (nimodipine IV) for aSAH; PDUFA target date April 23, 2026.
- U.S. patent issued for IV dosing regimen; IP protection extended to 2043.
- Cash $16.9M at Sept 30, 2025; ~$20.0M at Oct 31, 2025 after $4.0M warrant exercises.
- R&D expenses fell 80% to $0.6M due to completion of Phase 3 STRIVE-ON trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/0001140361-25-041807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036125041807/ef20058656_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-041807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer